Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2019 Jun 26

PMID 31236775

Citations 28

Authors

Sheila Annie Peters

Hugues Dolgos

Affiliations

Soon will be listed here.

Abstract

When scientifically well-founded, the mechanistic basis of physiologically based pharmacokinetic (PBPK) models can help reduce the uncertainty and increase confidence in extrapolations outside the studied scenarios or studied populations. However, it is not always possible to establish mechanistically credible PBPK models. Requirements to establishing confidence in PBPK models, and challenges to meeting these requirements, are presented in this article. Parameter non-identifiability is the most challenging among the barriers to establishing confidence in PBPK models. Using case examples of small molecule drugs, this article examines the use of hypothesis testing to overcome parameter non-identifiability issues, with the objective of enhancing confidence in the mechanistic basis of PBPK models and thereby improving the quality of predictions that are meant for internal decisions and regulatory submissions. When the mechanistic basis of a PBPK model cannot be established, we propose the use of simpler models or evidence-based approaches.

Citing Articles

Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs.

Rodriguez-Fernandez K, Gomez-Mantilla J, Shukla S, Mangas-Sanjuan V, Peters S Clin Pharmacokinet. 2025; .

PMID: 39899202 DOI: 10.1007/s40262-025-01472-w.

Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs.

Rodriguez-Fernandez K, Gomez-Mantilla J, Shukla S, Stopfer P, Sieger P, Mangas-Sanjuan V Clin Pharmacokinet. 2025; .

PMID: 39899201 DOI: 10.1007/s40262-025-01473-9.

Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.

Zbib F, Deschamps A, Velly L, Blin O, Guilhaumou R, Gattacceca F Clin Pharmacokinet. 2025; 64(2):257-273.

PMID: 39762592 DOI: 10.1007/s40262-024-01469-x.

From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling.

de Bruijn V, Rietjens I Arch Toxicol. 2024; 98(9):3077-3095.

PMID: 38755481 PMC: 11324677. DOI: 10.1007/s00204-024-03775-6.

Parameter grouping and co-estimation in physiologically based kinetic models using genetic algorithms.

Tsiros P, Minadakis V, Li D, Sarimveis H Toxicol Sci. 2024; 200(1):31-46.

PMID: 38637946 PMC: 11199918. DOI: 10.1093/toxsci/kfae051.

References

Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O . Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016; 5(3):93-122. PMC: 4809625. DOI: 10.1002/psp4.12049. View

Mao J, Doshi U, Wright M, Hop C, Li A, Chen Y . Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling. CPT Pharmacometrics Syst Pharmacol. 2018; 7(4):251-258. PMC: 5915609. DOI: 10.1002/psp4.12283. View

Huang S, Abernethy D, Wang Y, Zhao P, Zineh I . The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013; 102(9):2912-23. DOI: 10.1002/jps.23570. View

Peters S . Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet. 2008; 47(4):245-59. DOI: 10.2165/00003088-200847040-00003. View

Lappin G, Stevens L . Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol. 2008; 4(8):1021-33. DOI: 10.1517/17425255.4.8.1021. View

Yau E, Petersson C, Dolgos H, Peters S . A comparative evaluation of models to predict human intestinal metabolism from nonclinical data. Biopharm Drug Dispos. 2017; 38(3):163-186. PMC: 5412686. DOI: 10.1002/bdd.2068. View

Rowland M . Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e55. PMC: 3733532. DOI: 10.1038/psp.2013.29. View

Samant T, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A . Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations. Clin Pharmacol Ther. 2017; 104(2):374-383. PMC: 6099197. DOI: 10.1002/cpt.940. View

Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A . Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. Clin Pharmacol Ther. 2018; 104(1):88-110. PMC: 6032820. DOI: 10.1002/cpt.1013. View

10.

Peters S, Hultin L . Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn. 2007; 35(1):1-30. DOI: 10.1007/s10928-007-9073-1. View

11.

Tistaert C, Heimbach T, Xia B, Parrott N, Samant T, Kesisoglou F . Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies. J Pharm Sci. 2018; 108(1):592-602. DOI: 10.1016/j.xphs.2018.05.024. View

12.

Cubitt H, Yeo K, Howgate E, Rostami-Hodjegan A, Barter Z . Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica. 2011; 41(8):623-38. DOI: 10.3109/00498254.2011.560294. View

13.

Peters S . Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008; 47(4):261-75. DOI: 10.2165/00003088-200847040-00004. View

14.

Einolf H, Lin W, Won C, Wang L, Gu H, Chun D . Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions. Drug Metab Dispos. 2017; 45(12):1304-1316. DOI: 10.1124/dmd.117.076851. View

15.

Rose R, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M . Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e124. PMC: 4120018. DOI: 10.1038/psp.2014.24. View

16.

Grimstein M, Yang Y, Zhang X, Grillo J, Huang S, Zineh I . Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. J Pharm Sci. 2018; 108(1):21-25. DOI: 10.1016/j.xphs.2018.10.033. View

17.

Shebley M, Liu J, Kavetskaia O, Sydor J, de Morais S, Fischer V . Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. Drug Metab Dispos. 2017; 45(7):755-764. DOI: 10.1124/dmd.116.074518. View

18.

Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M . Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective. CPT Pharmacometrics Syst Pharmacol. 2017; 6(7):413-415. PMC: 5529733. DOI: 10.1002/psp4.12203. View

19.

Parkman H, Urbain J, Knight L, Brown K, Trate D, Miller M . Effect of gastric acid suppressants on human gastric motility. Gut. 1998; 42(2):243-50. PMC: 1726985. DOI: 10.1136/gut.42.2.243. View

20.

Johnson T, Zhou D, Bui K . Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm Drug Dispos. 2014; 35(6):341-52. DOI: 10.1002/bdd.1899. View